Skip to main content
Premium Trial:

Request an Annual Quote

Caprion Inks Proteomics Deal with AstraZeneca

NEW YORK, Aug. 11 (GenomeWeb News) - Caprion Pharmaceutials said today that it has signed a deal to use its proteomics technology to help AstraZeneca identify biomarkers for pain.


Under the arrangement, Montreal-based Caprion said it will use its CellCarta technology to profile, in specific preclinical models, proteomics changes in plasma that result from drug compound administration.


 "We believe that Caprion's proteomics platform is well suited to identify novel biomarkers that could be used to assess the safety and efficacy of AstraZeneca's experimental compounds," Philippe Walker, vice president of discovery at AstraZeneca R&D Montreal, said in a statement.


Specific terms of the arrangement were not disclosed.

The Scan

Mosquitos Genetically Modified to Prevent Malaria Spread

A gene drive approach could be used to render mosquitos unable to spread malaria, researchers report in Science Advances.

Gut Microbiomes Allow Bears to Grow to Similar Sizes Despite Differing Diets

Researchers in Scientific Reports find that the makeup of brown bears' gut microbiomes allows them to reach similar sizes even when feasting on different foods.

Finding Safe Harbor in the Human Genome

In Genome Biology, researchers present a new approach to identify genomic safe harbors where transgenes can be expressed without affecting host cell function.

New Data Point to Nuanced Relationship Between Major Depression, Bipolar Disorder

Lund University researchers in JAMA Psychiatry uncover overlapping genetic liabilities for major depression and bipolar disorder.